Actively Recruiting
A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors
Led by Weijia Fang, MD · Updated on 2025-05-31
30
Participants Needed
1
Research Sites
260 weeks
Total Duration
On this page
Sponsors
W
Weijia Fang, MD
Lead Sponsor
C
Chongqing Precision Biotech Co., Ltd
Collaborating Sponsor
AI-Summary
What this Trial Is About
This is a phase I clinical study to evaluate the safety and tolerability of CAR-T in patients with CD70-positive advanced/metastatic solid tumors, and to obtain the maximum tolerated dose of CAR-T and phase II Recommended dose.
CONDITIONS
Official Title
A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older, male or female
- Diagnosed with advanced or metastatic solid tumor with CD70-positive expression confirmed by pathology
- Disease progression or intolerance after standard treatments with no effective current treatment
- Presence of at least one measurable target lesion according to RECIST 1.1 criteria
- ECOG performance status between 0 and 2
- Expected survival time longer than 12 weeks
- No serious mental disorders
- Adequate organ function including hematopoietic, cardiac, renal, liver function, and oxygen saturation above 92%
- Suitable for apheresis or venous blood collection without contraindications
- Agreement to use reliable contraception methods for 1 year after CAR-T infusion
- Signed informed consent indicating understanding and willingness to participate
You will not qualify if you...
- Prior treatment with anti-CD70 drugs before screening
- Active or symptomatic central nervous system or meningeal metastases at screening
- Participation in other interventional clinical studies recently or recent use of unmarketed or marketed drugs within specified timeframes
- Recent anti-tumor therapies such as chemotherapy, targeted therapy, or corticosteroids above specified doses
- Receipt of live attenuated vaccines within 4 weeks before screening
- Active or uncontrolled infections requiring systemic treatment within 1 week before screening
- Malignant tumors other than the target tumor within past 3 years, except certain treated cases
- Serious heart conditions including advanced congestive heart failure, recent myocardial infarction, significant arrhythmias, or severe cardiomyopathy
- Active or uncontrolled autoimmune diseases
- Positive tests for certain infections including hepatitis B, hepatitis C, HIV, syphilis, or CMV
- History of venous thromboembolic events requiring ongoing anticoagulation or significant sequelae
- Poorly controlled hypertension despite treatment
- Pregnant or breastfeeding women or those planning to conceive within 1 year after CAR-T infusion
- Any other condition deemed inappropriate by investigators for study participation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
First affiliated hospital, Zhejiang University
Hangzhou, Zhejiang, China, 310006
Actively Recruiting
Research Team
W
Weijia Fang, M.D
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here